Loading
Scans at three months often cannot tell whether immunotherapy is working. A blood test at six weeks may give a clearer, earlier answer.
On-treatment ctDNA change at four to eight weeks predicted checkpoint outcomes across tumour types in several cohorts, including pan-cancer analyses, and outperformed early imaging in distinguishing pseudoprogression from true progression. The step never taken is a randomised trial in which the ctDNA result actually drives the decision to continue, intensify or switch.
Shares CD8 PET to stop or switch immunotherapy early, RECIST, Progression-free survival (PFS), Circulating tumour DNA (ctDNA).
Shares RECIST, Progression-free survival (PFS), Circulating tumour DNA (ctDNA), Trial design, endpoints and cost.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Liquid biopsy (ctDNA), Bladder & urothelial cancer.
Shares Molecular-progression switching beyond ESR1, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Molecular-progression switching beyond ESR1, Circulating tumour DNA (ctDNA), Trial design, endpoints and cost, MRD / molecular residual disease testing.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.